Andere Sprachen Ironwood Pharmaceuticals, Inc.

Aktien

A0X789

US46333X1081

IRWD

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:00:13 01.05.2024			% 5 Tage	% 1. Jan.
8,355 ^USD	+7,81 %		+2,59 %	-27,36 %

28.03.	Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals Inc. gibt positive Ergebnisse seiner explorativen Phase II STARGAZE-Studie mit Apraglutid bei Patienten mit steroidrefraktärer akuter gastrointestinaler Transplantat-gegen-Wirt-Krankheit (SR GI aGVHD) bekannt	CI
29.02.	Wall Street wird am Donnerstag höher eröffnen, da die Inflationsdaten die Prognosen erfüllen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024	13:33
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call	25.04.
La biotech helvétique a profité d'un regain de fonds en 2023	23.04.
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	28.03.
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	28.03.
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure	01.03.
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	29.02.
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	29.02.
Top Premarket Decliners	29.02.
Ironwood says bowel disease treatment meets main goal in late-stage trial	29.02.
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)	29.02.
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science and Practice Conference	26.02.
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference	23.02.
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results, Achieves 2023 Financial Guidance	16.02.
Ironwood Pharmaceuticals Insider Sold Shares Worth $2,699,979, According to a Recent SEC Filing	15.02.
Ironwood Pharmaceuticals Insider Sold Shares Worth $588,538, According to a Recent SEC Filing	15.02.
Ironwood Pharmaceuticals Insider Sold Shares Worth $722,071, According to a Recent SEC Filing	15.02.
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises	15.02.
Ironwood: Q4 Earnings Snapshot	15.02.
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ironwood Pharmaceuticals, Inc.

Aktien

A0X789

US46333X1081

IRWD

Andere Sprachen

Filter